Not So Benign: a Diet Pill Maker & Tumors in Rats, Arena Pharmaceuticals, Inc. Reveals

Last week, Arena Pharmaceuticals did some advance work surrounding the impending release of crucial data about its Lorqess diet pill, which was denied approval last fall by the FDA due, in part, to concerns the drug may cause tumors in rats and that efficacy was marginal. To allay those fears, the drugmaker conducted one new study and retained a group of independent pathologists to review other data (see this and this). The latest trial showed that concentrations of cerebrospinal fluid exposure were lower in human brains than in rat models given their pill (read here). The results prompted Needham analyst Alan Carr to write investors that the results “may alleviate certain FDA concerns with respect to the potential for brain tumors.”

MORE ON THIS TOPIC